公司概述
Elicio Therapeutics, Inc. operates as a clinical-stage biotechnology firm dedicated to the development of immunotherapies specifically designed for the treatment of cancer. The company's primary asset is its lead product candidate, ELI-002, which is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine currently undergoing Phase II clinical trials for seven indications involving the Kirsten rat sarcoma viral oncogene. This entity functions within the Healthcare sector, specifically targeting the Biotechnology industry, where high levels of scientific innovation and regulatory scrutiny define the competitive landscape. As of the latest available data, the company maintains a market capitalization of $189.30 million and employs a workforce of 33 individuals. The current market cap indicates that the firm is a small-cap entity with limited liquidity and high volatility, while the absence of reported annual revenue figures suggests the business is still in the research and development phase where revenue generation has not yet commenced.
财务健康
The company reports a net income of $-39,571,000 over the trailing twelve months, while revenue remains unreported, indicating a significant gap between top-line activity and bottom-line results driven entirely by operational expenses. EBITDA stands at $-37,510,000, reflecting substantial cash burn associated with advancing clinical trials and maintaining the research pipeline. Free cash flow is reported at $-21,666,376, which signifies that the company is consuming cash reserves to fund its operations rather than generating surplus liquidity from current activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard characteristic for pre-revenue biotechnology companies that have not yet achieved commercial sales. Regarding leverage, the company holds $18.56 million in cash against $14.51 million in debt, resulting in a debt-to-equity ratio of 887.04, which mathematically represents a highly leveraged balance sheet structure typical for asset-light biotech firms. The current ratio is 2.38, suggesting that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for operational continuity despite the lack of revenue. Return on Equity is listed as N/A due to the absence of net income, while Return on Assets is -87.2%, indicating that the company's asset base is currently generating negative returns.
估值评估
The P/E Ratio (TTM) is N/A because there is no earnings to value, whereas the Forward P/E is listed as -7.35, a negative figure that implies the market is pricing in future earnings recovery rather than current profitability. The Price to Book ratio is 111.85, a metric that indicates the market values the company at a significant premium over its net book value, reflecting the high potential value of its intellectual property and clinical pipeline. The Price to Sales ratio is N/A as there are no sales, and the EV/EBITDA stands at -4.94, further emphasizing the company's pre-profitability status and reliance on future cash flow generation. The stock's 52-week trading range spans from a low of $4.60 to a high of $14.93, with the current market price situated somewhere within this wide band, highlighting the high volatility inherent in small-cap biotechnology stocks. The Beta value of 1.88 indicates that the stock price is expected to fluctuate with significantly higher volatility than the broader market, moving approximately 1.88 times as much as the overall index in response to market shifts.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which is consistent with the company's pre-revenue status and the inability to calculate year-over-year percentage changes without historical sales data. Since there are no earnings to compare against revenue, the concept of earnings growing faster or slower than revenue does not apply in the traditional sense for a clinical-stage company. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that any potential cash flow is retained entirely for reinvestment into clinical trials and drug development rather than distribution to shareholders. Consequently, the overall growth and income profile of Elicio Therapeutics is defined by its capitalization of scientific progress and clinical trial milestones rather than current financial returns or dividend distributions.